
Zimmer Biomet Raises 2026 Guidance as Net Sales Climb 9.3% to $2.1 Billion
Zimmer Biomet Holdings, Inc.Description
What this story covers
Zimmer Biomet reported strong Q1 2026 results with 9.3% sales growth and significant margin expansion. Driven by its S.E.T. portfolio and Paragon 28 integration, the company raised full-year EPS guidance while returning $250 million to shareholders through buybacks.
Story snapshot
CompanyZimmer Biomet Holdings, Inc.
TickerZBH
VariantStandard detailed
Duration5:30
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-183411
Sources1
Full Story Script
Content not available for this story.